Stay updated on First-in-Human Study of EYP-1901 in wAMD Clinical Trial

Sign up to get notified when there's something new on the First-in-Human Study of EYP-1901 in wAMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the First-in-Human Study of EYP-1901 in wAMD Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:40:59.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dose levels of EYP-1901 in a Phase 1 study for patients with Wet Age Related Macular Degeneration (wAMD). This change reflects a modification in the bioactivity assessment and safety evaluation of the tyrosine kinase inhibitor in the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:02.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying the inclusion and exclusion criteria for subjects with wet Age-Related Macular Degeneration (wAMD). Previously, no information was provided regarding the participation criteria.
    Difference
    24%
    Check dated 2024-05-22T21:20:27.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:25:14.000Z thumbnail image

Stay in the know with updates to First-in-Human Study of EYP-1901 in wAMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the First-in-Human Study of EYP-1901 in wAMD Clinical Trial page.